HDAC9 and myeloproliferative disorder: Notably, cells with mutationally active JAK2 were more sensitive to HDAC inhibition, which also displayed efficacy in murine models of MPN as a monotherapy and elicited augmented therapeutic responses in combination with ruxolitinib [93,95,98].